Dipyridamole

cardiac valve replacement, Ischemic Attack, Transient, Coronary Disease + 9 more

Treatment

6 FDA approvals

12 Active Studies for Dipyridamole

What is Dipyridamole

Dipyridamole

The Generic name of this drug

Treatment Summary

Dipyridamole is a medication that prevents the body from absorbing and breaking down adenosine, a compound found in red blood cells and the walls of blood vessels. It also helps to increase the effectiveness of prostacyclin, a drug used to reduce the risk of blood clots.

Dipyridamole

is the brand name

image of different drug pills on a surface

Dipyridamole Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Dipyridamole

Dipyridamole

1980

98

Approved as Treatment by the FDA

Dipyridamole, also known as Dipyridamole, is approved by the FDA for 6 uses like Postoperative Thromboembolism and cardiac valve replacement .

Postoperative Thromboembolism

cardiac valve replacement

Venous Thrombosis

Stroke

Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid

Stroke

Used to treat previous stroke in combination with Acetylsalicylic acid

Transient Ischemic Attack (TIA)

Used to treat Transient Ischemic Attack in combination with Acetylsalicylic acid

Effectiveness

How Dipyridamole Affects Patients

Dipyridamole is a drug used to widen blood vessels and prevent blood clots, which can occur when someone has certain heart or blood vessel disorders. It is often taken with other drugs such as warfarin to help prevent thrombosis. Dipyridamole can also help show how well the heart is working, help prevent strokes, and reduce the risk of blood clots when combined with aspirin.

How Dipyridamole works in the body

Dipyridamole works by blocking the breakdown of cAMP, an inhibitor of platelet activity. By increasing cAMP levels, Dipyridamole prevents arachidonic acid from leaving cell membranes, and reduces the activity of thromboxane A2. It also stimulates the release of prostacyclin, which further raises the cAMP levels in platelets and further inhibits platelet aggregation.

When to interrupt dosage

The measure of Dipyridamole is contingent upon the distinguished condition, including Thrombosis, prior stroke and Stroke. The amount of dosage will be found in the table below, contingent upon the technique of administration (e.g. Tablet, coated or Capsule).

Condition

Dosage

Administration

cardiac valve replacement

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Ischemic Attack, Transient

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Coronary Disease

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Heart Valve Prosthesis

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Myocardial Perfusion Imaging

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Venous Thrombosis

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Anti-platelet Therapy

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Ischemic Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Stroke

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Diagnostic Imaging

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Transient Ischemic Attack (TIA)

, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg

Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Warnings

Dipyridamole Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Atrioventricular Block

Do Not Combine

Respiratory Sounds

Do Not Combine

There are 20 known major drug interactions with Dipyridamole.

Common Dipyridamole Drug Interactions

Drug Name

Risk Level

Description

Abrocitinib

Major

The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.

Acebutolol

Major

Dipyridamole may increase the bradycardic activities of Acebutolol.

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dipyridamole.

Alprenolol

Major

Dipyridamole may increase the bradycardic activities of Alprenolol.

Alprostadil

Major

The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.

Dipyridamole Toxicity & Overdose Risk

Low blood pressure may be a temporary side effect of drug overdose, but if needed, a medication to increase blood pressure can be administered. In rats, the lowest toxic dose is greater than 6,000mg/kg and in dogs it is roughly 400mg/kg. The lethal dose for a rat is 8.4g/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Dipyridamole Novel Uses: Which Conditions Have a Clinical Trial Featuring Dipyridamole?

38 active studies are currently assessing the potential of Dipyridamole to reduce Postoperative Thromboembolism, Stroke and Thrombosis.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Venous Thrombosis

0 Actively Recruiting

cardiac valve replacement

0 Actively Recruiting

Heart Valve Prosthesis

0 Actively Recruiting

Transient Ischemic Attack (TIA)

2 Actively Recruiting

Phase 4, Not Applicable

Diagnostic Imaging

0 Actively Recruiting

Ischemic Stroke

2 Actively Recruiting

Not Applicable

Ischemic Attack, Transient

0 Actively Recruiting

Anti-platelet Therapy

0 Actively Recruiting

Stroke

0 Actively Recruiting

Stroke

6 Actively Recruiting

Not Applicable, Phase 1

Myocardial Perfusion Imaging

1 Actively Recruiting

Phase 1

Dipyridamole Reviews: What are patients saying about Dipyridamole?

5

Patient Review

1/26/2013

Dipyridamole for Transient Ischemic Attack

I constantly had really severe headaches.

4.7

Patient Review

10/8/2013

Dipyridamole for Transient Ischemic Attack

migraines are the absolute worst. I get pain not just in my head, but also radiating down into my neck and sinuses, as well as across my eyes. Sometimes I even get tingling and weakness in my arms.

4.3

Patient Review

6/9/2009

Dipyridamole for Obstruction of a Blood Vessel by a Blood Clot

I wake up early with a severe headache that affects my temples, eyes, nose, and neck. I also feel nauseous. Symptoms go away by 10 or 11 a.m., but it's really debilitating while it lasts.

4

Patient Review

7/4/2010

Dipyridamole for Transient Ischemic Attack

I had a TIA and was ordered to take this medication twice daily. However, I have cut down to once a day because I can only remember to take it about two times per week.

3

Patient Review

1/9/2008

Dipyridamole for Prevention of Blood Clots in the Brain

2.3

Patient Review

5/6/2012

Dipyridamole for Transient Ischemic Attack

I experienced some headaches and muscle pain while using this medication. I also had difficulty breathing and nosebleeds.

1.3

Patient Review

11/27/2007

Dipyridamole for Transient Ischemic Attack

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dipyridamole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is dipyridamole an anticoagulant or antiplatelet?

"Dipyridamole is an antiplatelet agent used to prevent strokes and other blood clotting complications. It is often used in combination with warfarin after mechanical valve replacement surgery."

Answered by AI

Does dipyridamole contain aspirin?

"The recommended dose of Aggrenox is 1 capsule twice a day, with each capsule containing 25 mg of aspirin and 200 mg of dipyridamole."

Answered by AI

What class of drug is dipyridamole?

"Aspirin and extended-release dipyridamole work together as antiplatelet agents to reduce the risk of stroke. By preventing excessive blood clotting, the combination of these drugs help patients who have had or are at risk of stroke."

Answered by AI

Is dipyridamole still available?

"Although Boehringer Ingelheim announced that it would be discontinuing both Persantine and its authorized generic, dipyridamole, it is expected that there will be enough Persantine in pharmacies to last through May 2016 and enough dipyridamole to last through August 2017."

Answered by AI

Clinical Trials for Dipyridamole

Image of University of Michigan in Ann Arbor, United States.

Brain Stimulation for Stroke and Aphasia

18+
All Sexes
Ann Arbor, MI

The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is: * Does transcranial direct current stimulation (tDCS) administered to the pre-frontal areas of the brain improve post-stroke fatigue and aphasia? * What kinds of participant characteristics are associated with better improvement of post-stroke fatigue and aphasia? Researchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.

Recruiting
Device

University of Michigan (+1 Sites)

Image of Kessler Foundation in West Orange, United States.

Robotic Balance Training + Brain Stimulation for Stroke

18 - 75
All Sexes
West Orange, NJ

Our proposed study, "NEUROBALANCE Stroke,"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation. The study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies. The findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.

Recruiting
Device

Kessler Foundation

Vikram Shenoy Handiru,, PhD

Image of Brooks Rehabilitation Clinical Research Center in Jacksonville, United States.

Q Therapeutic System for Stroke

18 - 80
All Sexes
Jacksonville, FL

This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.

Recruiting
Has No Placebo

Brooks Rehabilitation Clinical Research Center

Emily Fox, PT, DPT, MHS, PhD

BrainQ Technologies Ltd.

Have you considered Dipyridamole clinical trials?

We made a collection of clinical trials featuring Dipyridamole, we think they might fit your search criteria.
Go to Trials

Have you considered Dipyridamole clinical trials?

We made a collection of clinical trials featuring Dipyridamole, we think they might fit your search criteria.
Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Low SAR MRI Scans for Coronary Heart Disease

18 - 100
All Sexes
Bethesda, MD

Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools. Objective: To test a new MRI scanner and software changes to create better pictures. Eligibility: People with disease and healthy volunteers, ages 18 and older. Design: Participants will be screened with blood tests. Participants may have both the new MRI and a conventional MRI or only the new one. If 2 are done, they must be within 60 days. For both MRI versions, participants lie on a table that slides into a large tube. During scans, they will hold their breath for up to 20 seconds at a time. Heart activity will be measured by wires connected to pads on the skin. A flexible belt may be used to monitor their breathing. They will be in the scanner up to 2 hours. Participants can agree to have a dye called gadolinium injected into their arm during the scan. This brightens the pictures. Participants can agree to take a drug called a vasodilator. This helps detect areas of the heart with abnormal blood supply. Scans of the heart are taken before, during, and after they get the medicine. The drug may cause temporary chest pain or shortness of breath. They may get other drugs to relieve these symptoms. Sponsoring Institution: National Heart, Lung, and Blood Institute

Recruiting
Has No Placebo

National Institutes of Health Clinical Center

Adrienne E Campbell, Ph.D.